ClinicalTrials.gg
RecruitingNCT06492785Updated Dec 5, 2025

Hyaluronic Acid-enriched Transfer Medium in Single Blastocyst Transfer

An interventional study of High Hyaluronic Acid concentrations (0.5 mg/ml) and Low Hyaluronic Acid concentrations (0.125 mg/ml) in Infertility, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
858
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.

Planned enrollment
20th of 107
858 · median 248
Started
2024
with 7 others
No phase
65 of 139
22 open now
Primary completion
2025-12
later than 8 of 40 live
Registered
112th of 139
by date
Lead sponsor
3 of 139
Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Among the 139 studies in Infertility with a site in China, this one is the 20th largest by planned enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2024, is one of 65 with no phase, reaches primary completion later than 8 of the 40 other live ones, and was the 112th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Infertility with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the live birth rates of high concentration of Hyaluronic Acid (0.5 mg/ml) transfer medium (EmbryoGlue®) to those containing low Hyaluronic Acid concentrations (0.125 mg/ml) (G2 medium) in women undergoing single fresh and frozen blastocyst transfer.

Read the detailed description

The single blastocyst-stage embryo transfer cycles will be randomised in a 1:1 allocation, with block sizes of 2 and 4 on the day of Embryo Transfer (ET). This randomisation process will be centrally managed via a web-based electronic data capture system and will be stratified according to the treatment center. The allocation sequence and the designated treatment will be completely concealed from the participating couples, clinicians - including those conducting the transfer procedures - and outcome assessors. Given the intrinsic viscous nature of EmbryoGlue, embryologists, who who are responsible for the procedures in the laboratory will not be subjected to blinding. Only at the end of the study, when data collection is completed, the allocation sequence will be revealed to the primary investigators.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Hyaluronate-enriched medium
  • live birth
  • Single blastocyst transfer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All cycles with single blastocyst transfer will be considered eligible
  2. Both fresh and cryopreserved embryo transfer cycles utilizing autologous oocytes
  3. No age restriction will be applied
  4. was signed

Exclusion criteria

Exclusion Criteria:

  1. Uterine anatomic anomalies
  2. Women with untreated hydrosalpines
  3. Once couples have been enrolled in the trial, subsequent cycles will not be incorporated.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
858 participants (estimated)

Study arms

  • Experimental
    Hyaluronic Acid(EmbryoGlue®)

    High HA concentrations (0.5 mg/ml)

    Biological: High Hyaluronic Acid concentrations (0.5 mg/ml)

  • Active comparator
    Hyaluronic Acid (G2 medium)

    Low HA concentrations (0.125 mg/ml)

    Biological: Low Hyaluronic Acid concentrations (0.125 mg/ml)

Interventions

  • BiologicalHigh Hyaluronic Acid concentrations (0.5 mg/ml)

    Hyaluronic Acid(EmbryoGlue®)

  • BiologicalLow Hyaluronic Acid concentrations (0.125 mg/ml)

    Hyaluronic Acid (G2 medium)

06

What researchers measure

Primary outcomes

  1. Live birth rate

    The primary outcome was Live birth rate per embryo transfer.

    Time frame: Live birth is defined as the birth of at least one live baby after 24 weeks of gestation.

Secondary outcomes

  1. Biochemical pregnancy

    Biochemical pregnancy is defined as serum beta-human chorionic gonadotropin β-hCG \> 20 IU/L 12 days after embryo transfer.

    Time frame: 12 days after embryo transfer.

  2. Clinical pregnancy

    Clinical pregnancy is defined as the presence of at least one gestational sac confirmed by ultrasonography (ectopic pregnancy is included as a clinical pregnancy).

    Time frame: 6-8 weeks after embryo transfer

  3. Ongoing pregnancy

    Ongoing pregnancy is defined as the presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.

    Time frame: after 12 weeks of gestation.

  4. Miscarriage

    Miscarriage is defined as spontaneous loss of an intrauterine pregnancy before 20 completed weeks of gestation.

    Time frame: 20 weeks of gestation.

  5. Ectopic pregnancy

    Ectopic pregnancy is defined as a pregnancy implanted outside the uterine cavity, diagnosed by ultrasonography, surgical visualization, or histopathology.

    Time frame: After 4 to 6 weeks of embryo transfer

  6. Multiple pregnancy

    Multiple pregnancy is defined as a pregnancy with two or more gestational sacs or fetal heartbeats at 7 weeks of gestation.

    Time frame: 7 weeks of gestation.

  7. hypertensive disorders in pregnancy

    Comprising essential hypertension; pregnancy induced hypertension; pre-eclampsia and eclampsia.

    Time frame: From 20 weeks of gestation up to at birth

  8. Placental implantation disorders

    Placental implantation disorders encompass placenta previa, placenta accreta spectrum, placental abruption and/or abnormal cord insertion

    Time frame: From 20 weeks of gestation up to at birth

  9. Preterm birth

    Delivery of a fetus at less than 37 and more than 28 weeks gestational age

    Time frame: At birth

  10. Preterm premature rupture of membranes

    Preterm premature rupture of membranes is defined as the leakage of amniotic fluid through the cervical os before 37 weeks of gestation and before the onset of labor

    Time frame: Before 37 weeks of gestation and before the onset of labor

  11. Mode of delivery

    Vaginal delivery or cesarean delivery

    Time frame: At birth

  12. Gestational age

    Gestational age recorded at delivery

    Time frame: At birth

  13. Birth weight

    Weight of baby born (grams)

    Time frame: At birth

  14. low birth weight

    Weight of baby born \< 2500 g

    Time frame: At birth

  15. Very low birth weight

    Weight of baby born \< 1500 g

    Time frame: At birth

  16. Mean birth weight

    By checking medical records

    Time frame: 1 year after embryo transfer

  17. Macrosomia

    Weight of baby born \> 4000 g

    Time frame: At birth

  18. Large for gestational age

    Birthweight \> 90th percentile

    Time frame: At birth

  19. Small for gestational age

    Birthweight \< 10th percentile

    Time frame: At birth

  20. Neonatal intensive care unit admission

    Safety outcome. Number of pregnancies for which newborn is admitted to the NICU

    Time frame: Birth up to 1 year

  21. Stillbirth or late fetal death

    Fetal death at 20 or more weeks' gestation

    Time frame: At birth

  22. Early neonatal death

    Time frame: Up to 28 days after birth

  23. Congenital anomaly or birth defect

    Any congenital anomalies detected in baby born

    Time frame: Birth to first year of life

07

Study locations

1 of 1 sites recruiting
  • IVF laboratory
    Xi'an, Shaanxi 710003, China
    Recruiting
08

References and documents

Publications

  • Cai H, Xu D, Wang Z, Huang B, Xue X, Bai H, Man Y, Lei D, Wu Q, Ni Y, Lei J, Shi J. Efficacy and safety of hyaluronic acid-enriched transfer medium in women undergoing single blastocyst transfer: a study protocol for a multicentre randomised controlled trial. BMJ Open. 2025 Nov 19;15(11):e104571. doi: 10.1136/bmjopen-2025-104571. PubMed 41263844 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 15 months is below that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Sep 13, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492785
Lead sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Collaborators
Jiangxi Maternal and Child Health Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Huazhong University of Science and Technology
Responsible party
He Cai (Principal Investigator, Northwest Women's and Children's Hospital, Xi'an, Shaanxi) — Principal investigator
First posted
Jul 9, 2024
Start date
Sep 13, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 5, 2025

Study contacts

He Cai, Doctor
Contact
caihe@bjmu.edu.cn
13581613908
Juanzi Shi, Doctor
study chair · Center for Reproductive Medicine, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion